[CAS NO. 446-72-0] Genistein

Name: Genistein
Brand: Arctom Scientific
SKU: HY-14596

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [446-72-0]

Distributor

Catalog

HY-14596

Brand

MCE

CAS

446-72-0

DESCRIPTION [446-72-0]

Overview

MDL	-
Molecular Weight	270.24
Molecular Formula	C15H10O5
SMILES	OC1=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=CC(O)=C1

For research use only. We do not sell to patients.

32 Publications Citing Use of MCE

Summary

Genistein, a soy isoflavone, is a multiple tyrosine kinases (e.g., EGFR ) inhibitor which acts as a chemotherapeutic agent against different types of cancer , mainly by altering apoptosis , the cell cycle, and angiogenesis and inhibiting metastasis.

IC50 & Target

EGFR

0.6 μM (IC ₅₀ , Cell Assay)

In Vitro

Genistein inhibits serum-stimulated growth of MCF-7 and T47D ER ⁺ cells with IC ₅₀ values of 7.6 and 8.7 μg/mL by dye exclusion, respectively, and 8.7 and 10.6 μg/mL by [ ³ H]thymidmne incorporation, respectively. These values are similar to the IC ₅₀ values of 9.4 and 7 μg/mL for MCF-7 and T47D ER ⁺ cells, respectively, obtained with the MTT assay. Additionally, Genistein at concentrations up to 20 μg/mL does not alter MTT mitochondrial reduction when compared to control cells in an 8 h incubation period. Furthermore, neither biochanin A or daidzein are found to interfere with the MTT assay at IC ₅₀ concentrations. Therefore, the MTT assay is valid for determining growth inhibition by Genistein at concentrations under 20 μg/mL in the systems studied ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the present study, the effective dose of morphine caused a significant decrease in testis weight of mice compared to Saline group (p=0.00). Moreover, testis weight are significantly increase in treated animals with Genistein and Genistein plus morphine in all doses in comparison with morphine group (p=0.028). Morphine caused a significant decrease in the testosterone, LH and FSH hormones compared to saline group (p=0.00). In addition, the testosterone, LH and FSH hormones increased significantly in Genistein (p<0.05) and Genistein plus morphine in all groups administration compared to morphine group (p=0.024) ^[2] . Bisphenol A (BPA) treatment alone and combined with Genistein had no significant effect on the protein expression of LC3II and PPARα in liver of STD- or HFD-fed rats (P>0.05; P>0.05). Significant decreasing of the protein expression of PPARγ in liver is observed when Genistein is added to rats, compared to either HFD group or HFD-BPA group ^[3] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT00244907	Purdue University\|National Center for Complementary and Integrative Health (NCCIH)\|Office of Dietary Supplements (ODS)	Osteoporosis\|Osteopenia	January 2006	Phase 1
NCT00951912	Sun Yat-sen University\|Chinese Nutrition Society\|Danone Institute International\|Department of Health of Guangdong Province	Type 2 Diabetes Mellitus	August 2009	Not Applicable
NCT02624388	University of Virginia	Lymphoma\|Childhood Lymphoma\|Solid Tumor\|Childhood Solid Tumor\|Neuroblastoma\|Ewing Sarcoma\|Hodgkin Lymphoma\|Non-Hodgkin Lymphoma\|Rhabdomyosarcoma\|Soft Tissue Sarcoma\|Medulloblastoma\|Germ Cell Tumor\|Wilms Tumor\|Brain Neoplasms\|Medulloblastoma, Childhood\|Neuroectodermal Tumors, Primitive	August 2016	Phase 2
NCT01489813	Emory University\|DSM Nutritional Products, Inc.	Bladder Cancer	May 19, 2017	Phase 2
NCT01556737	Wageningen University	Postmenopause	November 2011	Not Applicable
NCT00376948	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Pancreatic Cancer	May 2005	Phase 2
NCT00882765	Jonsson Comprehensive Cancer Center	Pancreatic Cancer	May 2009	Phase 2
NCT00001696	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Cancer	April 1998	Phase 1
NCT02499861	St. Justine´s Hospital	Cancer	July 2015	Phase 1\|Phase 2
NCT00584532	University of California, Davis	Prostate Cancer	November 2003	Phase 2\|Phase 3
NCT00546039	University Hospital, Aker	Prostatic Neoplasms	April 2007	Phase 2
NCT03040531	University of Messina\|Ministry of Health, Italy	Osteoporosis, Steroid Induced	January 19, 2017	Phase 2\|Phase 3
NCT04105023	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran\|National Council of Science and Technology, Mexico	Metabolic Syndrome\|Obesity	September 15, 2013	Not Applicable
NCT01982578	Fundación para la Investigación del Hospital Clínico de Valencia\|University of Valencia	Alzheimer´s Disease	September 1, 2017	Not Applicable
NCT01985763	Sofya Pintova\|DSM Nutritional Products, Inc.\|Icahn School of Medicine at Mount Sinai	Colon Cancer\|Rectal Cancer\|Colorectal Cancer	November 2013	Phase 1\|Phase 2
NCT01664650	University of Messina\|Ministry of Education, Universities and Research, Italy	Metabolic Syndrome	September 2008	Phase 2\|Phase 3
NCT02796794	TC Erciyes University	Sepsis	June 2015	Phase 4
NCT00355953	University of Messina	Menopause\|Osteopenia	January 2003	Phase 2\|Phase 3
NCT00058266	Northwestern University\|National Cancer Institute (NCI)	Prostate Cancer	December 2002	Phase 2
NCT00290758	National Cancer Institute (NCI)	Breast Cancer	January 2006	Phase 2
NCT00118040	National Cancer Institute (NCI)	Recurrent Bladder Carcinoma\|Stage I Bladder Cancer AJCC v6 and v7\|Stage II Bladder Cancer AJCC v6 and v7\|Stage III Bladder Cancer AJCC v6 and v7	June 24, 2005	Phase 2
NCT00287690	Imperial College London	Coronary Artery Disease	October 1999	Phase 2\|Phase 3
NCT01126879	Northwestern University\|National Cancer Institute (NCI)	Adenocarcinoma of the Prostate\|Recurrent Prostate Cancer\|Stage I Prostate Cancer\|Stage II Prostate Cancer\|Stage III Prostate Cancer	February 3, 2011	Phase 2
NCT01325311	National Cancer Institute (NCI)	Prostate Adenocarcinoma\|Stage I Prostate Cancer\|Stage IIA Prostate Cancer\|Stage IIB Prostate Cancer	December 2011	Phase 2
NCT01628471	Uman Pharma\|DSM Nutritional Products, Inc.\|MDEIE Ministry, Québec Government\|INRS-Institut Armand Frappier , Université du Québec	Non Small Cell Lung Cancer	November 2012	Phase 1\|Phase 2
NCT00626769	University of Messina\|Primus Pharmaceuticals	Menopause\|Osteopenia	July 2005
NCT00769990	Masonic Cancer Center, University of Minnesota	Breast Cancer\|Kidney Cancer\|Lung Cancer\|Melanoma\|Metastatic Cancer\|Pain\|Prostate Cancer	September 2008	Phase 1\|Phase 2
NCT01538316	University of Hohenheim\|University Hospital Tuebingen\|Quercegen Pharmaceuticals	Primary Prevention of Prostate Cancer	March 2012	Not Applicable
NCT00276835	Northwestern University\|National Cancer Institute (NCI)	Kidney Cancer\|Melanoma (Skin)	November 2005	Early Phase 1
NCT00541710	University of Messina\|Ministry of Education, Universities and Research, Italy	Metabolic Syndrome	October 2007	Phase 2\|Phase 3
NCT02766478	Emory University	Prostate Cancer	October 16, 2017	Phase 2
NCT00005827	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Prostate Cancer	December 1999	Phase 1
NCT00244933	Barbara Ann Karmanos Cancer Institute\|National Cancer Institute (NCI)	Breast Cancer	February 2004	Phase 2
NCT00590538	Children´s Hospital of Philadelphia\|Cystic Fibrosis Foundation	Cystic Fibrosis	February 2003	Phase 1\|Phase 2
NCT00269555	University of California, Davis	Prostate Cancer	May 2004	Not Applicable
NCT00000613	National Heart, Lung, and Blood Institute (NHLBI)	Bone Diseases\|Cardiovascular Diseases\|Coronary Disease\|Depression\|Heart Diseases\|Myocardial Ischemia\|Osteoporosis\|Postmenopause	April 1997	Phase 2
NCT00099008	UNC Lineberger Comprehensive Cancer Center\|National Cancer Institute (NCI)	Breast Cancer\|Endometrial Cancer	March 2004	Phase 1

Appearance

Solid

Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 370.04 mM )

H ₂ O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.7004 mL	18.5021 mL	37.0041 mL
5 mM	0.7401 mL	3.7004 mL	7.4008 mL
10 mM	0.3700 mL	1.8502 mL	3.7004 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 50% PEG300 >> 50% saline

Solubility: 5 mg/mL (18.50 mM); Suspended solution; Need ultrasonic
2.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 3.75 mg/mL (13.88 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution
4.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 3 mg/mL (11.10 mM); Clear solution

* All of the co-solvents are available by MCE.

References

Synonyms

4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-

Genistein

Isoflavone, 4′,5,7-trihydroxy-

5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one

C.I. 75610

Genisteol

Prunetol

Sophoricol

4′,5,7-Trihydroxyisoflavone

Genisterin

5,7,4′-Trihydroxyisoflavone

NPI 031L

Baichanin A

SIPI 807-1

NSC 36586

Bonistein

FW 635I-2

GeniVida

Climagen F

5,7-Dihydroxy-3-(4-hydroxyphenyl)-4H-chromen-4-one

Genistin aglycone

CSU-1999

CSU 1999

BIO 300